Atlas FDA

EXABLATE 2100 SYSTEM

FDA premarket approval P040003/S006 · decided 2009-12-22

Approval details

PMA number
P040003
Supplement
S006
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
EXABLATE 2100 SYSTEM
Generic name
Ablation system, high intensity focused ultrasound (HIFU), MR-guided
Applicant
Insightec, Ltd.
Date received
2009-06-05
Decision date
2009-12-22
Days to decision
200 days
Decision code
APPR
Product code
NRZ
Advisory committee
Obstetrics/Gynecology
Expedited review
No
Location
Dallas, TX
Statement
APPROVAL FOR ADDITION OF ENHANCED SONICATION, A DETACHABLE CRADLE, AND SEVERAL OTHER MODIFICATIONS TO THE EXABLATE 2000 SYSTEM. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME EXABLATE 2100 AND IS INDICATED FOR ABLATION OF UTERINE FIBROID TISSUE IN PRE- OR PERI-MENOPAUSAL WOMEN WITH SYMPTOMATIC UTERINE FIBROIDS WHO DESIRE A UTERINE SPARING PROCEDURE AND WHOSE UTERINE SIZE IS LESS THAN 24 WEEKS. PATIENTS SHOULD HAVE COMPLETED CHILD BEARING.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Exablate Model 2100V1, Exablate Prostate System, Exablate MRgFUS, Exablate 2100V1 Type 3.0 (K231378)Insightec, Ltd.2023-10-30